Answers are grounded in this paper and cite their sources.
With the "low hanging fruit" of early drug discovery gone, pharmaceutical companies are increasingly turning to developing high-throughput synthetic platforms capable of greatly shortening the design-make-test cycle of new drugs. Purification has long been considered the bottleneck of this procedure; however, new technologies and systems are now being integrated into these high-throughput synthetic workflows, providing compounds of high purity capable of being used directly in biological screening.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: